?Aggressive Care at the End of Life; Where Are We

Faculty Medicine Year: 2019
Type of Publication: ZU Hosted Pages:
Authors:
Journal: Indian Journal of Palliative Care Wolters Kluwer - Medknow Volume:
Keywords : ?Aggressive Care , , , , Life; Where , ,    
Abstract:
Background: Although, efforts to encourage palliative care only for terminal patients, aggressive end‑of‑life care (EOL) care still common for those probably to die shortly. Aim: Multicenter experiences to investigate where did we stand in this era? Patients and Methods: A retrospective study included patients with advanced solid tumors. The presence of one or more of the following indicators in the last month of life (LM) referred to aggressive EOL care: emergency department (ED) visits ≥ twice, admission to the hospital through ED, death in critical care units (CCUs), and palliative chemotherapy (PC) at the past 2 weeks before death. Results: A total of 435 patients, 51.5% were men with a median age of 62 years (range: 17–108), were included in the study. Most of the patients (89.2%) belonged to Group II; they had attended ED at least twice (60%), approximately 53% admitted to the hospital through ED, 31% received PC‑LM with 41% of them had at the past 2 weeks before death, 13% died in the CCUs, and more than half of them (53%) survived <2 weeks. Kaplan–Meier estimator revealed that median survival was 30 days in Group I versus 13 days in Group II (odds ratio: 1.63; 95% confidence interval: 1.20–2.21; P = 0.002). The median survival was statistically significantly associated with PC‑LM ≥14 days and the admission mode. There was no statistically significant association with age, sex, and primary cancer sites. Conclusion: The majority of our patients continue with anticancer treatments they possibly do not need and associated with poor survival.
   
     
 
       

Author Related Publications

  • Amarallah Abdelmoneim Mohamed Sayed, "Myelodysplastic syndrome from theoretical review to clinical application view", PAGEPress, Italy, 2018 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Patterns of Inpatient Admissions during Haj Clinical conditions, length of stay and patient outcomes at an advanced care centre in Makkah, Saudi Arabia", Pak J Med Sci, 2018 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Neoadjuvant Platinum and Gemcitabine Regimens Precede Definitive Radiotherapy in Locally Advanced Bladder Cancer", Symbiosis, 2019 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Efficacy and Safety of First-Line Pazopanib in Patients with Metastatic Renal Cell Carcinoma: Real-Life Multi Institutional Experience", Remedy Publications LLC, 2019 More
  • Amarallah Abdelmoneim Mohamed Sayed, "CDK4/6 inhibitors in advanced breast cancer, what is beyond?", PAGEPress, Italy, 2019 More

Department Related Publications

  • Foad Mohamed Mohamed Abotaleb, "الاحتفاظ بالمثانة البولية فى سرطان الخلايا الانتقالية التوسعى عن طريق الاستئصال الجزئى عبر قناة مجرى البول والعلاج الكيميائى سى . أم . ف", لايوجد, 1900 More
  • Foad Mohamed Mohamed Abotaleb, "المضاعفات الكبدية التى تحدث بعد عملية زرع النخاع العظمى الذاتى لمرضى سرطان الغدد الليمفاوية الذين يحملون الاجسام المضادة لفيروس الالتهاب الكبدى الوبائى من النوع سى", لايوجد, 1900 More
  • Shereen Mostafa Saleh Elshorbagy, "- Detection of Paroxysmal Hemogloinuria Clones In patients With Pancytopenia", . IJAR 3,12,866-875; 2015, 2015 More
  • Shereen Mostafa Saleh Elshorbagy, "- CD19 and CD56 Antigens Expression in Acute Myeloid Leukemia Identifies Patients with Prognosis in Egypt Adverse", . IJSR 5; 2016, 2016 More
  • Ahmed Abdelrehem Ahmed Abdulrihem, "Significance of PAX (CDX2) gene expression in adult acute Myeloid leukemia", http://www.journalijar.com/, 2015 More
Tweet